In Part 1, I admitted that I didn’t understand the regulatory difficulties facing Xlear nearly as well as I thought I did.
That wasn’t the first time I’d discovered a gap in my understanding.
A few years earlier, I had walked into a room full of specialist rhinologist surgeons and nurses, reasonably confident that I knew something they didn’t.
As it turned out, I was wrong.
The room was at the ENT department at Charing Cross Hospital in London, part of Imperial College Healthcare.
Xlear had invited me to speak to the team about xylitol nasal sprays. I managed to secure an hour of their time.
The promise of lunch may have helped.
What I hadn’t realised was that they were already using xylitol in their clinical practice.
An unexpected discovery
The surgical team explained that they were using Xlear’s xylitol-containing nasal irrigation sachets, prepared with sterile water, during surgery. They also provided patients with the preparation for use during the first week afterwards.
The lead surgeon was particularly knowledgeable about xylitol and its potential effects on biofilms.
I had expected to spend much of my hour introducing the science.
Instead, I found myself discussing it with people who had already incorporated a related product into their clinical routines.
They were also interested in the nasal sprays. The samples were enthusiastically received, and I understood that the team intended to recommend them to patients.
I left feeling that the meeting had gone rather well.
But looking back, I realise there were questions I never asked.
Why had they started using xylitol irrigation in the first place? Had they been influenced by published research, by another surgeon, or by their own clinical observations? Was this a formal departmental protocol or a practice developed within the team?
I still don’t know.
And perhaps more importantly, what did their use of the preparation actually tell me about its effectiveness?
At the time, I was interested in introducing a product to clinicians.
Today, I’m interested in understanding how knowledge reached those clinicians before I did.
I suspect there’s another story waiting to be uncovered there.
When experience becomes evidence
The Charing Cross encounter presents a problem that I suspect many clinicians will recognise.
We observe things happening in practice. We notice patterns. We hear patients describe improvements. Sometimes we change what we do.
But what exactly have we learned?
The surgeons’ use of xylitol told me that a specialist team considered it worth incorporating into its practice. Their knowledge of the biofilm literature suggested a scientific rationale behind their interest.
Yet neither observation demonstrated that xylitol irrigation improved postoperative outcomes compared with saline alone.
Nor could experience with irrigation sachets automatically establish the effectiveness of a nasal spray.
A laboratory study might demonstrate that xylitol affects bacterial behaviour or biofilm formation under particular experimental conditions. That could provide a reason to investigate its clinical potential.
But the human nose is not a laboratory dish.
And the presence of a plausible mechanism doesn’t establish that a finished product prevents infection or improves recovery.
I have encountered this distinction repeatedly during my years working with xylitol in dentistry.
Evidence relating to an ingredient is not necessarily evidence relating to every product containing that ingredient.
Equally, evidence of an effect in one clinical context cannot simply be transferred to another.
This is where my two perspectives begin to pull in slightly different directions.
The clinician in me is interested in what practitioners observe and whether their experience might point towards something useful.
The investigator wants to know what else could explain those observations.
Neither perspective is necessarily wrong.
But they are asking different questions.
One bottle, several possible claims
Returning to Nathan Jones’s concerns from Part 1, I began wondering what a regulator would actually be asked to assess.
Consider a nasal spray containing xylitol.
Suppose its manufacturer wants to describe it as helping to moisturise the nasal passages.
Now suppose the manufacturer wants to claim that it relieves particular nasal symptoms.
Or that it prevents a respiratory infection.
These are illustrative claims, not a verified list of Xlear’s current UK or European claims.
The bottle might be identical in each example. Its ingredients might be unchanged.
But what the manufacturer is asking the public to believe is different.
And that difference matters.
Then came COVID-19
During the pandemic, researchers in Utah and Geneva investigated whether Xlear’s nasal spray formulation could affect SARS-CoV-2 under laboratory conditions.
The findings appeared encouraging. Experiments reported reductions in viral infectivity when the formulation was tested against the virus.
But what had actually been demonstrated?
The experiments were conducted outside the human body.
They raised the possibility of a useful effect, but they did not establish that using the nasal spray would prevent COVID-19 or improve outcomes in infected patients.
And that distinction was about to become more than an academic question.
Xlear’s COVID-19 advertising claims subsequently attracted the attention of the US Federal Trade Commission.
The FTC challenged whether the evidence adequately substantiated the claims being made. Xlear disputed the allegations, and the legal proceedings were eventually dismissed in 2025 without a judicial determination of the spray’s clinical effectiveness.
Small clinical investigations also followed the laboratory work, adding further observations and questions to the developing evidence.
Suddenly, the relationship between an experimental observation and a public claim had become the subject of a real regulatory dispute.
How far could a manufacturer legitimately travel from this formulation affected a virus under laboratory conditions to this product protects people against infection?
The distinction might seem straightforward when written down.
But the journey between those statements is anything but simple.
Does the existing evidence count?
This brings us to something that initially troubled me.
If research has already been published on xylitol, why might a manufacturer need to undertake further studies?
Surely existing evidence should count for something?
The answer appears to be yes.
But precisely what it counts towards depends on the claim being made.
In Great Britain, the regulatory requirements for a nasal product depend on factors including its intended purpose and how its principal action is achieved. A product may fall within medical-device or medicines legislation, with different requirements applying.
The European Union has related but distinct frameworks.
Under the EU medical-device framework, for example, clinical evaluation can draw upon existing scientific literature and, where relevant requirements are met, evidence from equivalent devices. It does not automatically follow that every product requires an entirely new clinical trial.
But the evidence still needs to support the particular product and its intended purpose.
A laboratory study demonstrating an effect on a virus might support a proposed mechanism.
A clinical study examining nasal symptoms might investigate whether patients experience a benefit.
A controlled trial demonstrating that a particular spray reduces the risk of infection would address another question.
Those studies are not interchangeable.
This doesn’t mean the earlier research has no value.
It means we need to be careful about what we ask it to establish.
What about the people using it?
There is another part of the story I don’t want to lose.
People have been purchasing and using xylitol nasal products for years.
What should we make of that experience?
Sales figures might tell us that a product attracts customers. Repeat purchases might suggest that people find it useful or worthwhile. Reports of benefit might point towards effects that deserve investigation.
But none of those observations, by themselves, establishes that the product prevents a viral infection or produces a particular clinical outcome.
Equally, dismissing people’s experiences simply because they are not controlled clinical trials would seem unsatisfactory.
Those experiences may help us formulate questions, identify outcomes worth measuring and understand how products are used outside research settings.
Perhaps the question is not whether experience counts as evidence.
Perhaps it is what kind of evidence experience provides, and what further questions it allows us to ask.
Two sides of the Atlantic
Nathan’s original frustration concerned the different regulatory environments in which Xlear operates.
That makes the comparison between the United States and Europe unavoidable.
But I am becoming wary of reducing the disagreement to a simple story in which one regulator welcomes innovation while another obstructs it.
Both systems distinguish between products and the claims made about them. Both have processes for evaluating safety and effectiveness. Both can require manufacturers to substantiate what they say.
The differences lie in the details: classification, applicable legislation, permitted claims, evidence requirements and routes to market.
Before concluding that one system is unnecessarily restrictive, I would want to know exactly which claim Xlear wishes to make, how the product is classified in each market, what evidence has been submitted and what the relevant authorities have actually required.
I don’t yet have those answers.
Nor have I established the full regulatory history of Xlear’s nasal spray in the UK or EU, or the costs associated with any particular proposed claim.
Those gaps are important.
I began this investigation because Nathan’s account suggested a regulatory difficulty worth understanding.
It would be a mistake to turn his account into my conclusion before investigating it.
Back to Charing Cross
I keep returning to that meeting.
The surgeons were interested in xylitol’s potential benefits. They had incorporated a related irrigation preparation into their practice. They received the nasal sprays positively.
I had interpreted the meeting as a successful educational visit.
And perhaps it was.
But I now see something else.
The same encounter could be viewed in several ways.
To a clinician, it might be an example of professional judgement informed by scientific knowledge and experience.
To a researcher, it might be the beginning of a question about comparative effectiveness.
To a manufacturer, it might suggest an opportunity for further product development.
To a regulator, it would raise questions about the intended use and the evidence supporting any claims.
The encounter hasn’t changed.
What has changed is the boundary around which I am examining it.
I went to Charing Cross thinking I had something to teach.
I left having learned something unexpected.
Years later, I am discovering that I still have questions about what happened in that room.
And that brings me back to Xlear.
The question is no longer simply whether evidence exists. It is whether the evidence available can support the particular claim being made about the particular product.
That is a more demanding question.
It is also a more useful one.
But where did this particular journey begin?
The answer takes us back to a family physician, a young granddaughter suffering recurrent ear infections, and research into xylitol that had originally been conducted for quite different reasons.
I know something of that history.
What I don’t yet know is how the physician himself remembers it.
And that seems a good place for the next part of this investigation to begin.
Next in Evidence in Transit: From a Granddaughter to a Nasal Spray — How an Idea Begins to Travel
Disclosure: I have worked with Xlear in an educational capacity for many years and continue to receive payment from the company for educational work. Xlear has no editorial control over Evidence in Transit. The views, questions and interpretations expressed here are my own.

